Skip to main content
. 2012 Jun 9;2:25. doi: 10.1186/2191-219X-2-25

Table 3.

Cumulative biodistribution data of [111In]AT2S in AR4-2J and HEK293-hsst2A+, -hsst3+, and -hsst5+tumor-bearing SCID mice

[111In]AT2S (%ID/g tissue ± SD)
Organs
AR4-2J
HEK293-hsst2A+
HEK293-hsst3+
HEK293-hsst5+
 
1 h
4 h
4 h + Tatea
4 h
4 h + DP2b
4 h
4 h + AT2Sc
4 h
4 h + AT2Sc
Blood
1.34 ± 0.21
0.19 ± 0.02
0.26 ± 0.03
0.23 ± 0.07
0.66 ± 0.35
0.19 ± 0.03
0.2 ± 0.10
0.1 ± 0.04
0.23 ± 0.03
Liver
1.27 ± 0.09
0.95 ± 0.21
1.02 ± 0.11
1.31 ± 0.36
0.963 ± 0.67
1.02 ± 0.19
1.09 ± 0.2
1.1 ± 0.08
1.25 ± 0.09
Heart
0.67 ± 0.12
0.18 ± 0.05
0.17 ± 0.04
0.22 ± 0.05
0.38 ± 0.10
0.15 ± 0.04
0.15 ± 0.01
0.15 ± 0.02
0.18 ± 0.03
Kidneys
23.83 ± 4.28
21.10 ± 4.43
24.41 ± 9.15
23.20 ± 7.04
25.51 ± 3.70
23.42 ± 4.69
23.55 ± 8.96
24.12 ± 1.21
24.68 ± 2.20
Stomach
3.23 ± 0.77
1.81 ± 0.47
0.18 ± 0.07***
1.96 ± 0.53
1.29 ± 0.36
3.41 ± 0.97
0.19 ± 0.05***
3.06 ± 0.73
0.17 ± 0.2***
Intestines
1.98 ± 0.29
1.92 ± 0.25
0.77 ± 0.58*
2.00 ± 0.48
1.74 ± 1.02
2.39 ± 0.43
0.54 ± 0.2***
1.54 ± 0.09
0.57 ± 0.20***
Spleen
0.84 ± 0.21
1.10 ± 0.63
0.61 ± 0.18
0.46 ± 0.11
0.50 ± 0.36
0.82 ± 0.11
0.98 ± 0.23
0.78 ± 0.07
1.08 ± 0.16
Muscle
0.22 ± 0.02
0.06 ± 0.01
0.07 ± 0.01
0.07 ± 0.02
0.07 ± 0.03
0.06 ± 0.01
0.07 ± 0.02
0.06 ± 0.01
0.06 ± 0.02
Lung
2.05 ± 0.52
1.43 ± 1.36
3.30 ± 4.93
1.37 ± 0.55
0.47 ± 0.08
0.68 ± 0.29
0.73 ± 0.14
0.56 ± 0.28
0.83 ± 0.13
Femur
0.49 ± 0.12
0.40 ± 0.24
0.19 ± 0.02
0.24 ± 0.09
0.21 ± 0.11
0.23 ± 0.03
0.23 ± 0.04
-
-
Pancreas
7.35 ± 0.74
5.13 ± 0.75
0.15 ± 0.05**
5.73 ± 1.28
0.16 ± 0.10***
3.33 ± 0.4
0.11 ± 0.01***
2.79 ± 0.4
0.43 ± 0.54***
Tumor 3.05 ± 0.51 1.82 ± 0.36 0.21 ± 0.17*** 1.49 ± 0.2 0.27 ± 0.20*** 1.24 ± 0.27 0.32 ± 0.06*** 0.41 ± 0.12 0.22 ± 0.006*

*Significant (p < 0.05), and ** and ***highly significant (p < 0.005) difference between blocked and unblocked animals (Student’s t test). aCo-injection of 50 nmol Tate; bco-injection of 35 nmol DP2; cco-injection of 35 nmol AT2S.